ERBB2 and breast cancer: Trastuzumab/pertuzumab (HP) combination has become the cornerstone of neoadjuvant chemotherapy for breast cancer patients with HER2 overexpression, the combination of HP and EPI chemotherapy regimen can increase cardiac toxicity.